Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
Body unavailable. Use the original source.
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.